Table 1.
Systemic Damage Produced by Chronic Excessive Alcohol Consumption that Should be Considered in Subjects with ALD
| Digestive tract |
| Esophagitis |
| Acute and chronic gastritis |
| Acute and chronic pancreatitis |
| Gastrointestinal bleeding |
| Central and peripheral nervous system |
| Increase risk of hemorrhagic stroke |
| Sensitive motor polyneuropathy |
| Autonomic neuropathy |
| Wernicke's encephalopathy and related diseases |
| Alcohol‐related dementia |
| Alcohol withdrawal and delirium |
| Behavioral effects |
| Heart and vascular system |
| Hypertension |
| Increased ischemic peripheral vascular disease |
| Alcoholic cardiomyopathy |
| Subclinical |
| Diastolic dysfunction |
| Clinical (heart failure, arrythmias) |
| Sudden death |
| Bone and skeletal muscle |
| Osteoporosis |
| Skeletal myopathy |
| Subclinical |
| Clinical (muscle weakness, myalgia) |
| Nutritional status |
| Caloric malnutrition |
| Protein malnutrition |
| Vitamin, ionic, and mineral deficiencies |
| Pellagra |
| Endocrine‐metabolic dysfunction |
| Disruption of gonadal axis |
| Hypertriglyceridemia, increased HDL |
| Reduced insulin sensitivity |
| Plasma acidemia |
| Increased oxidative tissue stress |
| Fetal alcohol syndrome |
| Hemato‐immune dysfunction |
| Lymphocyte dysfunction |
| Immunocomplex induction |
| Altered phagocytic activity |
| Bone marrow dysplasia |
| Disruption of platelet aggregation and fibrinloysis (fibrinogen, plasminogen activator inhibitor) |
| Increased risk of infection (gram‐negative, mycobacterial) |
| Increased risk of cancer |
| Mouth |
| Larynx |
| Esophageal |
| Gastric |
| Colon‐rectum |
| Liver |
| Kidney |
| Breast |